5Wiley J, Ki67-structure,function and new antibodies[J].J Path, 1992,168(3) : 161-162.
6Huang G, Yan Q, Wang z, et al. Human cytomegalovirus in neoplastic cells of Epstein-Barr virus negative Hodgkin's disease [J ]. lnt J Oncol, 2002 , 21 ( 1 ) : 31-36.
7Razzaque A, Jahan N, McWeeney D, et al. Localization and DNA sequence analysis of the transforming domain (mtrII) of human cytomegalovirus [ J ]. Proc Natl Acad Sci USA, 1988,85 ( 15 ) : 5709- 5713.
8Doniger J, Muralidhar S, Rosenthal L J. Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate. Clin Microbiol Rev, 1999,12(3) :367-82.
9Jung J E, Kim T K, Lee J S, et al. Survivin inhibits anti-growth effect of p53 activated by aurora B [J]. Biochem Biophys Res Commun, 2005,336(4) : 1164-1171.
3Cerci JJ, Trindade E, Buccheri V, et al. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions. Clin Lymphoma Myeloma Leuk, 2011, 11(4): 314-320.
4Jaffe ES, Harris NL, Stein H, et al. Pathology&Genetics: tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001 : 239-244.
6Spaepen K, Stroobants S, Dupont P, et al. Early restaging positronemission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol, 2002, 13(9): 1356-1363.
7Wong CY, Thie J, Parling-Lyneh K J, et al. Glucose-normalized standardized uptake value from 18F-FDG PET in classifying lymphomas. J Nucl Med, 2005, 46( 10): 1659-1663.
8Stumpe KD, Urbinelli M, Steinert HC, et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med, 1998, 25(7 ) : 721-728.
9Jerusalem G, Hustinx R, Beguin Y, et al. Evaluation of therapy for lymphoma. Semin Nuel Med, 2005, 35 (3): 186-196.
10Gisselbrecht C, Mounier N, Andr6 M, et al. How to define intermediate stage in Hodgkin's lymphoma?. Eur J Haematol Suppl, 2005, (66): 111-114.
